Investment
Features
FeesSafety
Academy
More
Pluang+

Seneca Foods stock up 107.5% since June 2023 on strong growth and acquisitions, still undervalued.

Analyst Insights
23 Aug 2026
Seeking Alpha
View Source
Bullish
Seneca Foods stock up 107.5% since June 2023 on strong growth and acquisitions, still undervalued.

Seneca Foods Corporation's stock has surged 107.5% since June 2023, driven by strong revenue growth and profitability. In Q1 2027, revenue rose 36.2% with volume gains across core categories, supported by acquisitions like Green Giant's US frozen business. Despite this rally, Seneca Foods trades at the lowest valuation multiples among peers, indicating potential for further upside. The company's expansion beyond organic growth and attractive valuation make it a compelling buy for investors.

More News

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...

Company Fundamentals
Bullish
31 minutes ago
Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...

Company Fundamentals
Neutral
35 minutes ago
Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...

Market News
Bullish
35 minutes ago
Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...

Market News
Bearish
35 minutes ago
Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...

Analyst Insights
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App